These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38861592)

  • 21. The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma.
    Li X; Hou G; Zhu Z; Yan F; Wang F; Wei D; Zheng Y; Yuan J; Zheng W; Zhang G; Meng P; Guo Y; Li X; Yao L; Shen L; Yuan J
    Invest New Drugs; 2020 Aug; 38(4):956-966. PubMed ID: 31463638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mTOR inhibitors in advanced renal cell carcinoma.
    Voss MH; Molina AM; Motzer RJ
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):835-52. PubMed ID: 21763970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
    Alam MM; Marin Fermin J; Spiller PT; Burnett C; Rong X; Moore-Medlin T; Maxwell CO; Khandelwal AR; Nathan CO
    Mol Carcinog; 2022 Jan; 61(1):33-44. PubMed ID: 34598317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.
    Zheng B; Mao JH; Qian L; Zhu H; Gu DH; Pan XD; Yi F; Ji DM
    Cancer Lett; 2015 Feb; 357(2):468-75. PubMed ID: 25444920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Characteristics of Everolimus-resistant Renal Cell Carcinoma Cells Generated by Continuous Exposure to Everolimus.
    Nakayama Y; Enomoto D; Yamamoto K; Takara K
    Anticancer Res; 2023 Oct; 43(10):4349-4357. PubMed ID: 37772579
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma.
    Fujishita T; Kojima Y; Kajino-Sakamoto R; Taketo MM; Aoki M
    Oncogene; 2017 Nov; 36(46):6480-6489. PubMed ID: 28759045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma.
    Watari K; Nishitani A; Shibata T; Noda M; Kawahara A; Akiba J; Murakami Y; Yano H; Kuwano M; Ono M
    Oncotarget; 2016 Jul; 7(30):47403-47417. PubMed ID: 27329724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel
    Rodríguez-Moreno JF; Apellaniz-Ruiz M; Roldan-Romero JM; Durán I; Beltrán L; Montero-Conde C; Cascón A; Robledo M; García-Donas J; Rodríguez-Antona C
    J Natl Compr Canc Netw; 2017 Nov; 15(11):1310-1315. PubMed ID: 29118224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth.
    Koo J; Wang X; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
    Oncotarget; 2015 Apr; 6(11):8974-87. PubMed ID: 25797247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
    Elkabets M; Vora S; Juric D; Morse N; Mino-Kenudson M; Muranen T; Tao J; Campos AB; Rodon J; Ibrahim YH; Serra V; Rodrik-Outmezguine V; Hazra S; Singh S; Kim P; Quadt C; Liu M; Huang A; Rosen N; Engelman JA; Scaltriti M; Baselga J
    Sci Transl Med; 2013 Jul; 5(196):196ra99. PubMed ID: 23903756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.
    Voss MH; Bastos DA; Karlo CA; Ajeti A; Hakimi AA; Feldman DR; Hsieh JJ; Molina AM; Patil S; Motzer RJ
    Ann Oncol; 2014 Mar; 25(3):663-668. PubMed ID: 24458473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways.
    Son JY; Yoon S; Tae IH; Park YJ; De U; Jeon Y; Park YJ; Rhyu IJ; Lee BM; Chung KH; Lim JE; Lee SJ; Lee HW; Kwak JH; Kim HS; Choi HY
    Cancer Med; 2018 Oct; 7(10):5083-5095. PubMed ID: 30160042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
    Ellis L; Shah P; Hammers H; Lehet K; Sotomayor P; Azabdaftari G; Seshadri M; Pili R
    Mol Cancer Ther; 2012 Feb; 11(2):383-92. PubMed ID: 22084164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiating mTOR inhibitors in renal cell carcinoma.
    Pal SK; Quinn DI
    Cancer Treat Rev; 2013 Nov; 39(7):709-19. PubMed ID: 23433636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism.
    Juengel E; Makarević J; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    Neoplasia; 2014 Apr; 16(4):291-300. PubMed ID: 24862756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
    Wysocki PJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.
    Jiménez-Valerio G; Martínez-Lozano M; Bassani N; Vidal A; Ochoa-de-Olza M; Suárez C; García-Del-Muro X; Carles J; Viñals F; Graupera M; Indraccolo S; Casanovas O
    Cell Rep; 2016 May; 15(6):1134-43. PubMed ID: 27134180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.
    Figlin RA; Kaufmann I; Brechbiel J
    Int J Cancer; 2013 Aug; 133(4):788-96. PubMed ID: 23319457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1.
    Zhang C; Duan Y; Xia M; Dong Y; Chen Y; Zheng L; Chai S; Zhang Q; Wei Z; Liu N; Wang J; Sun C; Tang Z; Cheng X; Wu J; Wang G; Zheng F; Laurence A; Li B; Yang XP
    Clin Cancer Res; 2019 Nov; 25(22):6827-6838. PubMed ID: 31383732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
    Wu M; Si S; Li Y; Schoen S; Xiao GQ; Li X; Teh BT; Wu G; Chen J
    Oncotarget; 2015 Oct; 6(32):32761-73. PubMed ID: 26418749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.